INmune Bio Inc

NASDAQ INMB

Data sourced from iex and EODHD
Download Data

INmune Bio Inc Income Statement 2016 - 2024

This table shows the Income Statement for INmune Bio Inc going from 2016 until 2024. The income statement, also known as the profit and loss statement, is a financial statement that provides a summary of a company's revenues, expenses, and net income over a specific period (such as a quarter or a year). It shows the company's ability to generate revenue, manage expenses, and ultimately determine its profitability.
Income Statement Trend Unit 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2016-12-31
Revenue
M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 78 78 78 78 0 0 0 0 0 0 0 0 - -
Cost of Revenue
M - - - - - - - - - - - - - - - - - - 0 0 0 0 0 0 0 0 - -
Gross Profit
M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 78 78 78 78 0 0 0 0 0 0 0 0 - -
Operating Expenses
M 34 30 27 26 26 26 30 31 31 29 23 14 8 3 80 80 80 80 2 3 10 12 11 9 3 0 - -
Selling, General, and Administrative Expenses (SG&A)
M 10 10 10 9 9 9 9 9 9 9 8 8 7 6 6 6 6 7 7 6 10 11 10 9 3 1 0 0
Research and Development (R&D) Expenses
M 25 20 18 17 17 17 21 22 22 21 15 11 8 6 5 4 3 2 2 1 1 1 1 1 1 0 0 0
Other Operating Expenses
M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 78 78 78 78 0 0 0 0 0 0 0 0 - -
Costs and Expenses
M - - - - - - - - - - - - - - - - - - 2 3 10 12 11 9 3 0 - -
Operating Income
M -34 -30 -27 -26 -26 -26 -29 -31 -31 -29 -23 -19 -15 -12 -11 -10 -8 -8 -7 -6 -12 -12 -11 -10 -4 -1 0 -
Interest Expense
M 0 0 0 1 1 1 22 22 22 21 - - - 0 0 0 0 - - - - - - - - - - -
Non-operating Income/Expense
M 0 0 0 -1 -1 -1 -2 -2 -2 -1 -1 0 0 0 0 0 2 2 -12,438 -12,438 -12,440 -12,440 0 0 0 0 - -
EBT
M -34 -30 -27 -27 -27 -27 -31 -33 -33 -30 -24 -19 -15 -12 -11 -10 -8 -8 -7 -6 -11 -12 -11 -10 -4 -1 0 -
Income Tax Provision
M -11 0 -15 1 1 1 22 22 22 21 - - - - - - 2 2 2 2 0 0 0 0 0 0 - -
Income after Tax
M -23 -30 -13 -21 -28 -29 -54 -46 -38 -31 - - - - - - -2 -2 -4 -5 -10 -12 -11 -9 -3 0 - -
Non-Controlling Interest
M 0 0 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 - -
Net Income
M -7 -13 -19 -27 -27 -27 -31 -33 -33 -30 -24 -19 -15 -12 -11 -10 -8 -8 -7 -6 -11 -12 -11 -9 -3 0 - -
Shares (Basic, Weighted)
M - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Shares (Diluted, Weighted)
R 17,982,884.75 17,962,765.25 17,807,416.00 17,791,841.00 17,791,841.00 17,772,913.50 17,772,913.50 17,618,759.50 16,875,999.00 15,989,092.50 14,888,382.50 13,787,672.50 12,744,111.25 11,850,271.50 11,305,461.75 10,764,445.25 10,601,970.75 10,262,307.00 10,380,342.25 10,494,584.25 10,761,742.00 11,219,441.00 11,219,441.00 11,219,441.00 11,219,441.00 11,219,441.00 11,219,441.00 -
EBITDA
M -34 -30 -27 -26 -26 -26 -29 -31 -31 -29 -23 -19 -15 -12 -11 -10 -11 -11 -10 -9 -12 -12 -11 -10 -4 -1 0 -
Depreciation and Amortization
M 5 0 23 1 0 0 -22 -22 -22 -21 - - - - - - -3 -3 -3 -3 - - - - - - - -
EBIT
M -39 -30 -50 -27 -27 -27 -8 -10 -10 -8 -24 -19 -15 -12 -11 -10 -8 -8 -7 -6 -11 -12 -11 -9 -3 0 - -
Income from Discontinued Operations
M - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Tax Rate (Effective)
% 30.45 5.04 48.30 -2.88 -3.81 -4.92 -59.18 -77.70 -113.25 -220.35 - - - - - - -384.02 -384.02 -192.01 -128.01 0.00 0.00 0.00 0.00 0.00 0.00 - -
Earnings Per Share (EPS), Basic
M - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Earnings Per Share (EPS), Diluted
M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 - -
Gross Profit Margin
% 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 - - - - - - - - - -
Operating Income Margin
% -35,596.84 -20,149.29 -14,122.16 -11,062.75 -17,559.76 -14,327.66 -14,258.50 -28,468.71 -40,980,987.46 -41,008,418.90 -41,014,382.91 -54,664,365.31 -71,547.97 -29,395.93 -3.00 -3.00 -3.00 -3.00 - - - - - - - - - -
Net Income Margin
% -14,132.61 -15,666.30 -12,448.67 -11,307.17 -18,458.39 -15,217.13 -15,197.06 -30,115.69 -41,613,181.31 -41,640,597.57 -41,646,452.79 -55,506,084.68 -71,627.02 -29,354.03 -2.98 -2.98 -2.98 -2.98 - - - - - - - - - -
EBITDA Ratio
% -35,596.84 -20,149.29 -14,122.16 -11,062.75 -17,559.76 -14,327.66 -14,258.50 -28,468.71 -40,980,987.46 -41,008,418.90 -41,014,382.91 -54,664,365.31 -71,547.97 -29,395.93 -3.00 -3.00 -3.00 -3.00 - - - - - - - - - -
EBIT Ratio
% -44,639.22 -13,744.11 -27,088.39 -11,360.94 -17,857.95 -14,625.85 -10,990.10 -25,980.66 -40,978,499.41 -41,005,980.85 -41,015,202.79 -54,664,418.01 -71,627.02 -29,354.03 -2.98 -2.98 -2.98 -2.98 - - - - - - - - - -
EBT Ratio
% -35,706.28 -20,318.78 -14,314.99 -11,307.17 -18,458.39 -15,217.13 -15,197.06 -30,115.69 -41,613,181.31 -41,640,597.57 -41,646,452.79 -55,506,084.68 -71,627.02 -29,354.03 -2.98 -2.98 -2.98 -2.98 - - - - - - - - - -

StockViz Staff

September 20, 2024

Any question? Send us an email